Daiichi Sankyo sends team into Ranbaxy plant; Teva, P&G JV partners with VMS maker Swisse Wellness;

> The consumer healthcare joint venture of Teva Pharmaceutical Industries ($TEVA) and Procter & Gamble ($PG) has partnered with Australian vitamins, minerals, and supplements (VMS) maker Swisse Wellness. Story

> The Centers for Disease Control and Prevention (CDC) has agreed to import Bexsero, Novartis' ($NVS) meningitis B vaccine that is approved in Europe and Australia but not the U.S., for use in an outbreak of meningitis that has spread through the Princeton University community. Story

> The Technology Centre for Barrier Isolation Systems of Telstar in the U.K. has developed and manufactured a high containment barrier system for Komipharm Pharmaceuticals, an Asian manufacturer of oncology drugs. Release

> Indian drugmaker Ipca Laboratories says it has a deal to buy a 50% interest in active pharmaceutical ingredient (API) manufacturer Avik Pharmaceutical. Report

And Finally... Daiichi Sankyo, the majority owner of India's Ranbaxy Laboratories, has sent a team of 5 to Ranbaxy's Mohali plant to make improvements to the facility which the U.S. FDA in September tagged with an import alert. Story

Launch Readiness

Optimize cross-functional collaboration and engage with key stakeholders for the successful launch of a product

Join the Launch Readiness for Medical Affairs & Communications Teams Summit to learn best practices in taking a structured approach to enhance medical affairs activities surrounding a launch and increase knowledge and communication with thought leaders.